Thales Helps Microsoft Customers Protect Their Sensitive Data in the Cloud
16.3.2021 12:00:00 EET | Business Wire | Press release
Thales announces a new data protection capability for Microsoft customers to benefit from the power of the full range of Microsoft 365 applications while protecting sensitive data in the cloud and meeting major data privacy regulations and requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005009/en/
Copyright Thales
Designed for companies that operate in highly-regulated sectors such as financial services and healthcare, they can now leverage Thales Luna Hardware Security Modules (HSMs) with Double Key Encryption for Microsoft 365 and comply with regulations such as the EU General Data Protection Regulation (GDPR), the Health Insurance Portability and Accountability Act (HIPAA), and the recommendations from the European Data Protection Board (EDPR) following the Schrems II ruling.
Securing Data in the Era of Remote Working and Increased Privacy Regulations
Today’s remote working environment relies heavily on the collaborative sharing of information, challenging organisations to maintain the security of confidential data and regulatory compliance while driving employee productivity. For organisations in highly regulated industries such as financial services, governments, and healthcare, their sensitive data requires the highest level of control and security. The integration of Luna HSMs with Double Key Encryption for Microsoft 365 delivers the protection required to protect highly sensitive data and meet unique regulatory requirements.
“The premise of remote working is no longer a perk reserved for a select few, but now the default operating model for many companies,” said Imran Mohiuddin, DKE partner director at Microsoft. “Our collaboration and productivity tools for Microsoft 365 customers are designed to enable companies to thrive in any situation. A key part in enabling this to happen though is ensuring they have the best security and compliance solutions when it comes to protecting sensitive data. Our Double Key Encryption integration with Thales enables customers who have enhanced data protection requirements, compliance obligations and regulatory restrictions to protect their highly sensitive information. By having full control of their encryption keys, customers can be certain that no third-party has access to their unencrypted data -- including Microsoft. Security should never be something that holds companies back in this remote era and from moving their sensitive information to the cloud, and with Thales, we’re ensuring it won’t for our customers.”
Thales has integrated its industry-leading Luna HSMs with Microsoft Double Key Encryption for Microsoft 365. This allows customers to protect their most confidential or sensitive data while maintaining control of their encryption keys in the cloud. The solution works by using two keys to protect data. One key is managed securely by the customer via the Luna HSM and a second key in Microsoft’s control. To view the data, one must have access to both keys, meaning it can’t be used without the customer’s permission.
“Our collaboration with Microsoft is designed to give peace of mind to customers when it comes to security, no matter where or what Microsoft applications they’re accessing,” said Todd Moore, vice president of encryption solutions at Thales. “The way we work has changed forever and in order to thrive, businesses have had to increasingly adapt and adopt collaborative applications. The integration of Thales Luna HSMs with Microsoft Double Key Encryption provides businesses with control over their encrypted data, in line with regulatory requirements, regardless of their industry.”
|
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions. Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
|
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005009/en/
Contact information
PRESS
Thales, Media Relations
Market
Laura Bandiera
+33 (0)7 64 48 51 64
laura.bandiera@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
